Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United StatesIPO:
26 August 2022Website:
http://www.paxmedica.comNext earnings report:
09 August 2024Last dividends:
N/ANext dividends:
N/APrice
regular market | Wed, 26 Jun 2024 16:47:21 GMTDividend
Analysts recommendations
Institutional Ownership
PXMD Latest News
PaxMedica (NASDAQ: PXMD) has jumped 92.7% on Friday following the company's announcement of significant advancements in its drug development program, which has been well-received by the market.
PaxMedica stock is surging on Friday following the achievement of a significant milestone in drug development, with the company successfully obtaining three crucial batches of PAX-101.
PaxMedica (NASDAQ: PXMD ) stock is cratering today after the company announced a $7 million public offering. The offering consists of 5.38 million shares and warrants to purchase up to 5.38 million shares.
PaxMedica (NASDAQ: PXMD ) stock is jumping significantly higher against the backdrop of another soft session on Wall Street. This morning, management announced a productive discussion with the U.S. Food and Drug Administration (FDA) over positive clinical trial results for a key drug.
Clinical-stage biopharmaceutical firm PaxMedica (NASDAQ: PXMD ) is experiencing a full range of emotions following an initial spike in the market today. Earlier this morning, the company announced encouraging top-line results from its Phase 3 trial of PAX-101 (intravenous suramin), which met its primary endpoint.
What type of business is PaxMedica Common Stock?
PaxMedica, Inc., a clinical stage biopharmaceutical company, focuses on the development of anti-purinergic drug therapies (APT) for the treatment of disorders with intractable neurologic symptoms. The company's lead product candidate is PAX-101, an intravenous formulation of suramin for various indications, including autism spectrum disorder, myalgic encephalomyelitis/chronic fatigue syndrome, long COVID-19 syndrome, and human african trypanosomiasis. It is also involved in developing PAX-102, an intranasal formulation of suramin for neurologic indications. The company was formerly known as Purinix Pharmaceuticals LLC and changed its name to PaxMedica, Inc. in April 2020. PaxMedica, Inc. was incorporated in 2018 and is based in Tarrytown, New York. PaxMedica, Inc. operates as a subsidiary of Tardimed Sciences LLC.
What sector is PaxMedica Common Stock in?
PaxMedica Common Stock is in the Healthcare sector
What industry is PaxMedica Common Stock in?
PaxMedica Common Stock is in the Biotechnology industry
What country is PaxMedica Common Stock from?
PaxMedica Common Stock is headquartered in United States
When did PaxMedica Common Stock go public?
PaxMedica Common Stock initial public offering (IPO) was on 26 August 2022
What is PaxMedica Common Stock website?
https://www.paxmedica.com
Is PaxMedica Common Stock in the S&P 500?
No, PaxMedica Common Stock is not included in the S&P 500 index
Is PaxMedica Common Stock in the NASDAQ 100?
No, PaxMedica Common Stock is not included in the NASDAQ 100 index
Is PaxMedica Common Stock in the Dow Jones?
No, PaxMedica Common Stock is not included in the Dow Jones index
When does PaxMedica Common Stock report earnings?
The next expected earnings date for PaxMedica Common Stock is 09 August 2024